马来酸曲美布汀联合谷维素治疗肠易激综合征meta分析

吴映秀; 李辉标; 陈慕媛; 唐洪梅<sup>*</sup>

引用本文:	吴映秀,李辉标,陈慕媛,唐洪梅.马来酸曲美布汀联合谷维素治疗肠易激综合征meta分析[J].中国现代应用药学,2020,37(9):1106-1113.
	WU Yingxiu,LI Huibiao,CHEN Muyuan,TANG Hongmei.Meta-analysis on Trimebutine Maleate Combined with Oryzanol in Treating Irritable Bowel Syndrome[J].Chin J Mod Appl Pharm(中国现代应用药学),2020,37(9):1106-1113.

【打印本页】【HTML】【下载PDF全文】【查看/发表评论】【EndNote】【RefMan】【BibTex】

←前一篇|后一篇→

过刊浏览高级检索

本文已被：浏览 20859次下载 10362次	码上扫一扫！
分享到：微信更多字体:加大+\|默认\|缩小-
马来酸曲美布汀联合谷维素治疗肠易激综合征meta分析
吴映秀¹, 李辉标², 陈慕媛², 唐洪梅²
1.广州中医药大学第一临床医学院, 广州 510405;2.广州中医药大学第一附属医院, 广州 510405

摘要:

目的系统评价马来酸曲美布汀联合谷维素治疗肠易激综合征（irritable bowel syndrome，IBS）的有效性和安全性。方法通过Cochrane Library、Springer Link、中国期刊全文数据库、PubMed、Embase、中国生物医学文献数据库、万方数据库、中国科技期刊全文数据库检索马来酸曲美布汀联合谷维素治疗IBS的随机对照试验（randomized controlled trials，RCTs）。由2名评价者独立进行资料提取并根据Cochrane协作网偏倚风险评价标准进行文献质量评价，通过RevMan 5.3软件进行meta分析。结果共纳入15个RCTs，1 338例患者。Meta结果显示，与对照组相比，马来酸曲美布汀联合谷维素治疗IBS有更好的临床疗效[RR=1.26，95%CI（1.20，1.33），P<0.000 01]，可改善临床症状，腹痛[SMD=-0.94，95%CI（-1.22，-0.66），P<0.000 01]、腹泻[SMD=-1.33，95%CI（-1.68，-0.98），P<0.000 01]、日均排便次数[SMD=-1.41，95%CI（-1.79，-1.03），P<0.000 01]、大便性状异常比例[SMD=-2.82，95%CI（-3.42，-2.22），P<0.000 01）]，可降低不良反应[RR=0.40，95%CI（0.27，0.60），P<0.000 1]。结论与马来酸曲美布汀相比，马来酸曲美布汀联合谷维素治疗IBS临床疗效更优，不良反应更低。

关键词: 马来酸曲美布汀谷维素肠易激综合征 meta分析

DOI：10.13748/j.cnki.issn1007-7693.2020.09.016

分类号:R969.3

基金项目:国家自然科学基金项目（81673842）

Meta-analysis on Trimebutine Maleate Combined with Oryzanol in Treating Irritable Bowel Syndrome

WU Yingxiu¹, LI Huibiao², CHEN Muyuan², TANG Hongmei²

1.The First Clinical School of Guangzhou University of Chinese Medicine, Guangzhou 510405, China;2.The First Affiliated Hospital of Guangzhou University of Chinese Medicine, Guangzhou 510405, China

Abstract:

OBJECTIVE To systematically evaluate the efficacy and safety of trimebutine maleate combined with oryzanol in treating irritable bowel syndrome(IBS). METHODS Randomized controlled trials(RCTs) of trimebutine maleate combined with oryzanol in treating IBS were identified by searching electronic databases including Cochrane Library, Springer Link, CNKI, PubMed, Embase, CBM, Wanfang Data and VIP Database. Two reviewers extracted data independently and assessed literature quality according to the Cochrane Collaboration Risk Assessment Criteria and meta-analysis was conducted by using RevMan 5.3 software. RESULTS A total of 15 RCTs were included, involving 1 338 patients. The results of meta-analysis showed that compared with the control group, trimebutine maleate combined with oryzanol had better clinical efficacy[RR=1.26, 95%CI(1.20, 1.33), P<0.000 01], and improved clinical symptoms, abdominal pain[SMD=-0.94, 95%CI(-1.22, -0.66), P<0.000 01], diarrhea[SMD=-1.33, 95%CI(-1.68, -0.98), P<0.000 01], daily average number of bowel movements[SMD=-1.41, 95%CI(-1.79, -1.03), P<0.000 01], abnormal proportion of stool characteristics[SMD=-2.82, 95%CI(-3.42, -2.22), P<0.000 01)], and reduced adverse reactions[RR=0.40, 95%CI(0.27, 0.60), P<0.000 1] in the treatment of IBS. CONCLUSION Trimebutine maleate combined with oryzanol has better clinical efficacy and lower adverse reactions compared with trimebutine maleate in the treatment of IBS.

Key words: trimebutine maleate oryzanol irritable bowel syndrome meta-analysis